An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka, Stephen Wright GW Pharmaceuticals, Cambridge, UK Abstract: The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-year...

Full description

Bibliographic Details
Main Authors: Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Sativex
nabiximols
THC:CBD
multiple sclerosis
spasticity
registry
Online Access:https://www.dovepress.com/an-observational-postmarketing-safety-registry-of-patients-in-the-uk-g-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/an-observational-postmarketing-safety-registry-of-patients-in-the-uk-g-peer-reviewed-article-TCRM

Similar Items